Melatonin Enhances Autophagy to Suppress Hypertrophic Scar Formation

Study Background and Research Question

Hypertrophic scars (HS) arise from excessive fibrogenesis following skin injury, characterized by abnormal proliferation of fibroblasts and excessive extracellular matrix (ECM) deposition. Standard therapies, including surgical and non-surgical interventions, frequently fail to provide satisfactory outcomes, underscoring the need for novel, mechanism-based strategies. Previous work has implicated impaired autophagy in fibrotic disease progression and suggested that enhancing autophagy can mitigate fibrotic tissue dysfunction. Melatonin, an endogenous indoleamine with antioxidant, anti-inflammatory, and pro-autophagic properties, has shown antifibrotic effects in several organ systems, but its mechanistic impact on cutaneous fibrosis remained unclear. The central research question addressed in the reference study is whether melatonin can suppress hypertrophic scar formation by modulating fibroblast activity through autophagy enhancement, and if so, via which signaling pathways.

Key Innovation from the Reference Study

The study's primary innovation lies in demonstrating that melatonin inhibits human hypertrophic scar fibroblast (HSF) function and hypertrophic scar formation by enhancing autophagy, specifically through the MT2 receptor-mediated inhibition of the PI3K/Akt/mTOR pathway. Importantly, the mechanistic dissection revealed that melatonin disrupts the interaction between the MT2 receptor and PI3K (p110β), leading to downstream attenuation of Akt/mTOR signaling and upregulation of autophagic flux. This direct link between melatonin, MT2 receptor activity, and the autophagy pathway in the context of skin fibrosis had not been previously established.

Methods and Experimental Design Insights

The research employed a combination of in vitro and in vivo approaches. Human hypertrophic scar fibroblasts (HSFs) were isolated and treated with melatonin, with subsequent assessment of cellular migration, contraction, collagen synthesis, and α-smooth muscle actin (α-SMA) expression. RNA-sequencing and bioinformatic analysis were conducted to identify gene expression changes related to autophagy and oxidative stress. Mechanistic studies included the use of pharmacological inhibitors (such as the autophagy inhibitor 3-methyladenine, the Akt activator SC79, and the MT2 antagonist 4-phenyl-2-propionamidotetralin) to dissect pathway dependencies. An in vivo rabbit ear model of hypertrophic scarring was used to confirm the antifibrotic effects of melatonin under physiological conditions.

Protocol Parameters

• Melatonin treatment: Applied to primary human HSFs in vitro at concentrations validated for cell viability and pathway specificity; in vivo administration in rabbit ear model followed established dosing schedules.
• Autophagy inhibition: 3-MA (3-methyladenine) used to block autophagy, verifying the dependence of melatonin's effects on autophagic flux.
• Akt activation: SC79 employed to reactivate Akt signaling, counteracting the autophagy-promoting effects of melatonin.
• MT2 receptor antagonism: 4-P-PDOT administered to determine the requirement of MT2 receptor signaling for observed outcomes.
• Assessment of ROS and autophagy: Standard protocols for intracellular ROS detection with fluorogenic probes (e.g., DCFH-DA derivatives), and immunoblotting or immunostaining for autophagy markers such as LC3-II and p62.

Core Findings and Why They Matter

Melatonin treatment significantly reduced migration, contraction, collagen, and α-SMA production in HSFs, indicating suppression of profibrogenic functions. RNA-seq analysis revealed that melatonin modulates gene expression towards enhanced autophagy and reduced oxidative stress. Mechanistically, melatonin inhibited Akt/mTOR pathway activation by blocking MT2 receptor interaction with PI3K, thereby promoting autophagy. The antifibrotic effects of melatonin were reversed by autophagy inhibition, Akt activation, or MT2 receptor antagonism, confirming the specificity of the pathway. In vivo, melatonin attenuated hypertrophic scar formation in the rabbit ear model. These findings highlight autophagy enhancement as a viable therapeutic strategy for HS and position melatonin as a promising, mechanistically validated antifibrotic agent.

Comparison with Existing Internal Articles

This research aligns with broader trends in redox and fibrosis biology, as reflected in several internal resources. For example, internal discussions of 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) emphasize its utility for intracellular ROS detection and its role in autophagy-linked redox assays in fibrosis models. While the reference study primarily investigates autophagy and fibrotic signaling, RNA-seq data suggest melatonin's parallel modulation of oxidative stress, a process measurable with ROS fluorescent probes such as DCFH-DA. Relatedly, insights from protocol optimization articles provide guidance for maximizing signal fidelity in ROS assays, which may be directly applicable for mechanistic extensions of the present study. Additionally, studies such as LSKL-mediated modulation of PI3K/AKT in ovarian oxidative stress reinforce the translational significance of targeting similar signaling axes in fibrotic and metabolic diseases.

Limitations and Transferability

While the data robustly support the role of melatonin in autophagy-mediated inhibition of hypertrophic scarring, several limitations warrant consideration. The in vitro findings, though validated in a rabbit model, may not fully capture the complexity of human skin fibrosis, including immune and vascular components. The specificity of the MT2-PI3K/Akt/mTOR axis may vary across cell types and fibrotic contexts, and off-target effects of pharmacological agents cannot be excluded. Furthermore, the study did not directly quantify dynamic changes in intracellular ROS levels, which could provide additional mechanistic insight given melatonin's known redox-modulatory properties. Transferability to clinical scenarios will require further validation in human trials and exploration of optimal dosing regimens, especially considering the multifactorial nature of HS pathogenesis.

Research Support Resources

For researchers aiming to investigate oxidative stress, autophagy, and redox signaling in fibrotic models, reliable tools are essential. 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA, SKU C3890) from APExBIO is a widely used, cell-permeable fluorogenic probe for quantifying intracellular ROS across fluorescence microscopy, flow cytometry, and plate-based assays. Its application is especially relevant for studies exploring the intersection of ROS production, autophagy, and fibrosis, as highlighted in both the reference study and internal workflow discussions. For optimal assay design, consult established protocols and ensure the inclusion of appropriate experimental controls to address probe specificity and potential artifacts.